European Congress of Rheumatology 2021 (EULAR 2021) VIRTUAL

Results of the phase III, placebo-controlled ProDERM trial reported at EULAR 2021 showed significant efficacy and acceptable safety for immunoglobulin therapy given intravenously (IVIg) to patients with dermatomyositis – a systemic autoimmune disease marked by progressive proximal muscle weakness and a distinctive skin rash.

There is no evidence so far that patients with rheumatic and musculoskeletal diseases (RMDs) are at an increased risk of COVID-19 or have a worse prognosis, says a rheumatology expert at EULAR 2021.